Cooper Companies generated $1,066.2 million in quarterly Revenue and $432.8 million in Net Income for the three months ended July 31, 2026. Basic and Diluted Earnings per Share were both $2.24. Revenue was broadly stable from $1,060.3 million, while stronger segment sales and a higher gross Margin supported the reported profit.
Key Highlights
- Basic and diluted earnings per share were both $2.24 for the quarter.
- CooperVision contributed $717.0 million of quarterly revenue, while CooperSurgical generated $349.2 million.
- Cash and cash equivalents stood at $154.7 million at July 31, 2026.
COOPER COMPANIES, INC. (NASDAQ: COO) generated $1,066.2 million in revenue and $432.8 million in net income for the three months ended July 31, 2026. Revenue was up from $1,060.3 million in the comparable quarter. Basic and diluted earnings per share both came to $2.24.
Quarterly Revenue and Profit
CooperVision produced $717.0 million in quarterly sales, compared with $718.4 million in the comparable period. CooperSurgical revenue reached $349.2 million, up from $341.9 million. Toric and multifocal products generated $363.8 million, while Sphere and other products contributed $353.2 million. Within CooperSurgical, Office and surgical revenue was $208.0 million and Fertility revenue was $141.2 million. Net income was $432.8 million, compared with $98.3 million in the comparable quarter. Comprehensive income was $412.8 million, compared with $98.5 million. Cash Flow hedges produced a loss of $1.5 million, while foreign currency translation reduced comprehensive income by $18.5 million. Basic shares used to calculate earnings per share were 193.0 million, compared with 199.3 million. Diluted shares were 193.4 million, compared with 200.0 million. Basic and diluted earnings per share were each $2.24, compared with $0.49 for both measures in the comparable period.
Product Sales Shape Results
Toric and multifocal revenue increased to $363.8 million from $358.8 million. Sphere and other revenue fell to $353.2 million from $359.6 million, primarily because of lower legacy hydrogel sales. CooperVision’s Americas revenue was $281.6 million, compared with $286.0 million. EMEA sales reached $309.4 million, up from $292.1 million, while Asia Pacific revenue was $126.0 million, compared with $140.3 million. The company said Americas sales declined because of reductions in U.S. channel inventory. CooperSurgical’s Office and surgical revenue rose from $204.8 million to $208.0 million, primarily on increased surgical product sales. Fertility revenue increased from $137.1 million to $141.2 million, helped by higher genetic testing revenue and partly offset by lower equipment sales. Foreign exchange movements reduced sales across all categories by approximately $2.8 million during the quarter. In the comparable period, foreign exchange movements increased sales by approximately $26.8 million.
Margin and Operating Expenses
Gross profit was $711.9 million, compared with $692.0 million. Cost of sales declined to $354.3 million from $368.3 million, while gross margin rose to 67% from 65%. Selling, general and administrative expense was $401.3 million, compared with $421.7 million. Research and Development expense was $41.6 million, compared with $44.6 million. Amortization of Intangibles was $47.0 million, compared with $50.0 million. Operating Income reached $222.0 million, compared with $175.7 million. CooperVision operating income was $205.5 million, compared with $202.6 million, while CooperSurgical reported operating income of $41.1 million after an operating loss of $4.2 million in the comparable period. Corporate Operating Expense was $24.6 million, compared with $22.7 million. The company attributed the CooperVision operating-income increase primarily to lower operating expenses that more than offset lower sales.
Cash, Debt and Liquidity
Cash and cash equivalents totaled $154.7 million at July 31, 2026. Working Capital was $414.9 million, compared with $993.6 million at October 31, 2025, with the decrease primarily due to higher short-term debt. For the first nine months of 2026, Operating Activities generated $785.4 million of cash, compared with $548.2 million in the comparable period. Investing activities used $262.7 million, compared with $274.1 million, while financing activities used $476.6 million, compared with $261.5 million. The company said Operating Cash Flow increased primarily because of higher cash inflows from net income after adjustments for a non-cash discrete income tax benefit and an accrued litigation liability. The revolving Credit Facility had a $2,300 million limit, $966.7 million of outstanding borrowings and $5.3 million of outstanding letters of credit. Total availability was $1,328 million, with Maturity on May 1, 2029. The 2021 Term Loan had $550.0 million outstanding and matured on December 17, 2026. A second 2021 Term Loan had $950.0 million outstanding and matures on February 3, 2031. Across the facilities, the total limit was $3,800 million, outstanding borrowings were $2,466.7 million, outstanding letters of credit were $5.3 million and total available capacity was $1,328 million. Cooper Companies was in compliance with all debt covenants at July 31, 2026.




Please wait processing your request...